Dynavax Technologies Stock (NASDAQ: DVAX)

Dynavax Technologies (NASDAQ:DVAX) Stock, Quote.Headers.trade-ideas

Dynavax Technologies

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

DVAX

Biotech

News

Health Care

Movers

Trading Ideas

General

Latest regulatory update from Dynavax on HEPLISAV-B vaccine regimen for adults on hemodialysis, with FDA&#39;s Complete Response Letter.

FDA Declines To Approve Expanded Use of Dynavax&#39;s Hepatitis B Vaccine In Hemodialysis Patients

Penny Stocks

Small Cap

Intraday Update

Markets

AMAM

AMPE

ARBK

ARDX

AREN

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXNX

BCRX

BFLY

BNZI

BSGM

CROX

CYCC

DADA

ELEV

FSLY

HARP

LMDX

NEXI

NKTX

PACB

PRAX

PRTA

RGNX

RVNC

RXST

SHPH

SILK

SNMP

SPEC

STSS

STTK

TCJH

TREE

UPWK

VERO

VINC

ZJYL

Shares of  RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates.

Also, Needham maintained a Buy rating on the stock and raised its price target from $35 to $41.

Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Long Ideas

Media

IONQ

TALO

On CNBC’s &#34;Mad Money Lightning Round,&#34; Jim Cramer said  Restaurant Brands International Inc.  (NYSE: QSR) is a buy.

Cramer Suggests Buying Fast Food Chain Owner Of Popeye&#39;s, Burger King: Here&#39;s Why

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies Corp

Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $25.5, a high estimate of $29.00, and a low estimate of $15.00. This current average represents a 4.67% decrease from the previous average price target of $26.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1723132810_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Dynavax Technologies by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul Choi</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Dynavax Technologies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Dynavax Technologies compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Dynavax Technologies's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Dynavax Technologies's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DVAX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Dynavax Technologies analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Dynavax Technologies</h2>
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
<h3>Dynavax Technologies: A Financial Overview</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining Dynavax Technologies's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 22.48% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Dynavax Technologies's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 15.43% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Dynavax Technologies's ROE excels beyond industry benchmarks, reaching 1.81%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Dynavax Technologies's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.14% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Dynavax Technologies's debt-to-equity ratio stands notably higher than the industry average, reaching 0.39. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Assessing Dynavax Technologies: Insights From 4 Financial Analysts

Goldman Sachs analyst Paul Choi maintains Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) with a Neutral and lowers the price target from $20 to $15.

Price Target

Goldman Sachs Maintains Neutral on Dynavax Technologies, Lowers Price Target to $15

HC Wainwright &amp; Co. analyst Edward White reiterates Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) with a Buy and maintains $29 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Dynavax Technologies, Maintains $29 Price Target

Guidance

Dynavax Reaffirms 2024 HEPLISAV-B Net Product Revenue Guidance Of $265M-$280M

Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.06 by 33.33 percent. This is a 166.67 percent increase over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $73.795 million which missed the analyst consensus estimate of $76.102 million by 3.03 percent. This is a 22.48 percent increase over sales of $60.249 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Dynavax Technologies Q2 2024 GAAP EPS $0.08 Beats $0.06 Estimate, Sales $73.795M Miss $76.102M Estimate

Management

Dynavax Reappoints Kelly MacDonald As CFO Effective August 1, 2024; Ryan Spencer Continues As CEO After Serving As Interim CFO During MacDonald's Maternity Leave; No Change In MacDonald's Compensation

Dynavax Initiates Phase 1/2 Study Of Novel Shingles Vaccine Program Evaluating Safety, Tolerability And Immunogenicity Of Z-1018

Tuesday,&nbsp;Dynavax Technologies Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>)&nbsp;provided a regulatory update for its supplemental Biologics License Application (sBLA) to include a four-dose HEPLISAV-B vaccine regimen for adults on hemodialysis.&nbsp;
The FDA has issued a Complete Response Letter stating that the application did not provide sufficient data to fully evaluate the effectiveness or safety of a four-dose regimen of HEPLISAV-B.&nbsp;
The CRL has no impact on the approved indication for HEPLISAV-B in the U.S., the European Union, and&nbsp;Great Britain, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18&nbsp;years of age&nbsp;and older.&nbsp;
The CRL also does not affect the approval decision&nbsp;received from&nbsp;the European Commission in&nbsp;October 2023&nbsp;for the four-dose HEPLISAV-B&nbsp;regimen for the adult hemodialysis population.
The supplemental application included clinical immunogenicity and safety data from the Phase 1 HBV-24 study of a four-dose regimen of HEPLISAV-B in 119 adults undergoing hemodialysis, as well as five supportive clinical trials of HEPLISAV-B in adults with chronic kidney disease or undergoing hemodialysis.&nbsp;
The CRL stated that the data from HBV-24&nbsp;were insufficient&nbsp;due to the destruction of data source documents by a third-party clinical trial site operator for approximately half of the subjects enrolled in the trial.&nbsp;
In addition, the total number of subjects in the single-arm HBV-24 study&nbsp;was&nbsp;deemed&nbsp;insufficient&nbsp;to evaluate the four-dose regimen&#8217;s safety.
&#8220;We are reviewing the agency&#8217;s feedback and intend to request a meeting with the FDA to evaluate options for providing additional data to support the four-dose regimen for this vulnerable patient population in the U.S.,&#8221; said&nbsp;Rob Janssen,&nbsp;Dynavax&#8217;s Chief Medical Officer.
In&nbsp;first quarter&nbsp;2024,&nbsp;HEPLISAV-B vaccine&nbsp;achieved net product revenue of&nbsp;$47.8 million&nbsp;up from&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/n38711968/dynavax-reports-first-quarter-2024-financial-results-and-provides-business-updates" rel="noreferrer noopener">$43.5 million&nbsp;a year ago</a>.
HEPLISAV-B&nbsp;total estimated market share in the U.S. increased to approximately 41%, compared to approximately 37% at the end of the first quarter&nbsp;2023.
Price Action:&nbsp;At last check on Tuesday, DVAX shares were down 1.36% at $10.88.

FDA Declines To Approve Expanded Use of Dynavax's Hepatitis B Vaccine In Hemodialysis Patients

FDA Issued Complete Response Letter To Dynavax Saying sBLA For Four-Dose HEPLISAV-B Regimen Did Not Provide Sufficient Data To Support Full Evaluation Of Effectiveness Or Safety

WIIM

Dynavax shares are trading lower after the company reported worse-than-expected Q1 financial results.

<ul>
<li>HEPLISAV-B net product revenue between approximately&nbsp;$265&nbsp;-&nbsp;$280 million, including approximately&nbsp;$3 million&nbsp;in ex-U.S. sales through commercialization partnership in Germany&nbsp;</li>
<li>HEPLISAV-B gross margin of approximately&nbsp;80%</li>
</ul>

Dynavax Reaffirms Full Year 2024 Financial Guidance; Expects Cash & Equivalents To Be Higher Y/Y At December 31, 2024

Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.03) by 133.33 percent. The company reported quarterly sales of $50.790 million which missed the analyst consensus estimate of $54.975 million by 7.61 percent. This is a 8.24 percent increase over sales of $46.925 million the same period last year.

Dynavax Technologies Q1 2024 GAAP EPS $(0.07) Misses $(0.03) Estimate, Sales $50.790M Miss $54.975M Estimate

Dynavax Technologies Sees FY24 Net Product Revenue $265M-$280M Vs $290.628M Est.

Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) reported its Q4 earnings results on Thursday, February 22, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Dynavax Technologies missed estimated earnings by 100.0%, reporting an EPS of $0.0 versus an estimate of $-0.01.
Revenue was down $128.90 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.11 which was followed by a 1.07% increase in the share price the next day.
Here's a look at Dynavax Technologies's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.01</td>
<td>-0.09</td>
<td>-0.13</td>
<td>0.43</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.10</td>
<td>0.03</td>
<td>-0.19</td>
<td>0.45</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>60.30M</td>
<td>48.38M</td>
<td>38.59M</td>
<td>179.60M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>69.51M</td>
<td>60.25M</td>
<td>46.92M</td>
<td>184.49M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Dynavax Technologies <a href="https://www.benzinga.com/quote/DVAX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Dynavax Technologies: Q4 Earnings Insights

Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) reported quarterly sales of $55.60 million which beat the analyst consensus estimate of $52.73 million by 5.44 percent. This is a 69.87 percent decrease over sales of $184.49 million the same period last year.

Dynavax Technologies Q4 Sales $55.60M Beat $52.73M Estimate

Goldman Sachs analyst Paul Choi initiates coverage on Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) with a Neutral rating and announces Price Target of $20.

Initiation

Goldman Sachs Initiates Coverage On Dynavax Technologies with Neutral Rating, Announces Price Target of $20

Shares of RxSight, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rxst#NASDAQ">RXST</a>) rose sharply during Monday&rsquo;s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates.
Also, Needham maintained a Buy rating on the stock and raised its price target from $35 to $41.
RxSight shares jumped 20% to $44.31 on Monday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Harpoon Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/harp#NASDAQ">HARP</a>) shares jumped 111.2% to $22.28 after Merck announced it will acquire the company for $23 per share in cash.</li>
<li>Ambrx Biopharma Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amam#NASDAQ">AMAM</a>) jumped 98.1% to $27.00 after Johnson &amp; Johnson announced it will acquire the company in an all-cash merger for a total equity value of approximately $2 billion.</li>
<li>Spectaire Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spec#NASDAQ">SPEC</a>) jumped 75.2% to $2.96.</li>
<li>Nkarta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nktx#NASDAQ">NKTX</a>) rose 51% to $9.17 as the company announced updated corporate presentation to reflect business and strategic update.</li>
<li>Universe Pharmaceuticals INC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/upc#NASDAQ">UPC</a>) gained 42% to $2.22.</li>
<li>Elevation Oncology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elev#NASDAQ">ELEV</a>) jumped 39.2% to $1.2193.</li>
<li>NexImmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nexi#NASDAQ">NEXI</a>) rose 34.7% to $8.32.</li>
<li>Praxis Precision Medicines, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prax#NASDAQ">PRAX</a>) rose 34% to $33.76 as the company issued update on advancing clinical stage portfolio.</li>
<li>QuantaSing Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qsg#NASDAQ">QSG</a>) gained 31% to $2.0563.</li>
<li>Butterfly Network, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bfly#NASDAQ">BFLY</a>) rose 29.7% to $1.31 as the company announced FDA clearance of handheld ultrasound system, Butterfly iQ3.</li>
<li>Venus Concept Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vero#NASDAQ">VERO</a>) climbed 28% to $1.51.</li>
<li>Ardelyx, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ardx#NASDAQ">ARDX</a>) gained 25.5% to $7.73 after the company provided an update on its progress in 2023 and initial expectations for 2024.</li>
<li>BioCryst Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcrx#NASDAQ">BCRX</a>) rose 20.8% to $7.36 after the company issued preliminary Q4 revenue guidance above estimates. Also the company said it is approaching positive EPS and cash flow in 2H 2025.</li>
<li>Axonics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axnx#NASDAQ">AXNX</a>) jumped 19.9% to $69.03 after the company announced a deal to be acquired by Boston Scientific.</li>
<li>Crocs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crox#NASDAQ">CROX</a>) jumped 18.8% to $102.69 after the company issued strong Q4 and full year 2023 guidance.</li>
<li>LendingTree, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tree#NASDAQ">TREE</a>) rose 17.3% to $33.50.</li>
<li>Wolverine World Wide, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/www#NYSE">WWW</a>) jumped 16.7% to $9.02. Wolverine Worldwide affirmed preliminary 2023 financial results in line with guidance.</li>
<li>Ampio Pharmaceuticals, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ampe#NYSE">AMPE</a>) gained 16.4% to $2.0799 after falling around 8% on Friday.</li>
<li>Shattuck Labs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sttk#NASDAQ">STTK</a>) gained 15.2% to $9.52.</li>
<li>Vincerx Pharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vinc#NASDAQ">VINC</a>) shares rose 14.3% to $1.36 after the company announced compelling clinical efficacy of enitociclib in combination with venetoclax and prednisone in lymphoma.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cycc#NASDAQ">CYCC</a>) shares gained 14.1% to $2.84 after jumping over 10% on Friday.</li>
<li>Silk Road Medical, Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/silk#NASDAQ">SILK</a>) rose 13.4% to $12.91.</li>
<li>OPKO Health, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/opk#NASDAQ">OPK</a>) jumped 12.5% to $1.00.</li>
<li>Avadel Pharmaceuticals plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avdl#NASDAQ">AVDL</a>) gained 12% to $16.68 after the company issued a business update.</li>
<li>Fastly, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsly#NYSE">FSLY</a>) jumped 10.5% to $17.88 after RBC Capital upgraded the stock from Underperform to Sector Perform and raised its price target from $12 to $18.</li>
<li>Upwork Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/upwk#NASDAQ">UPWK</a>) gained 10.3% to $15.51 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $13 to $20.</li>
<li>Commercial Metals Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cmc#NYSE">CMC</a>) rose 6.2% to $51.21 following strong quarterly results.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>LumiraDx Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lmdx#NASDAQ">LMDX</a>) shares fell 45.5% to $0.0187. LumiraDx announced its securities will be suspended from trading on Nasdaq at the open of business on Jan. 9th.</li>
<li>Top KingWin Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcjh#NASDAQ">TCJH</a>) dipped 38.8% to $1.18.</li>
<li>Solo Brands, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dtc#NYSE">DTC</a>) dipped 38.7% to $3.6150 after the company lowered full year 2023 revenue guidance below estimates.</li>
<li>Dada Nexus Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dada#NASDAQ">DADA</a>) shares dipped 38.1% to $1.95. Dada Nexus said in the course of its routine internal audit, certain suspicious practices were identified that may cast doubt on certain revenues from the company&#39;s online advertising and marketing services in 2023.</li>
<li>Prothena Corporation plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prta#NASDAQ">PRTA</a>) fell 25.1% to $30.45 after the company issued updates on PRX012, PRX123, Birtamimab and Portfolio programs.</li>
<li>Jin Medical International Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zjyl#NASDAQ">ZJYL</a>) fell 23.4% to $95.00.</li>
<li>MMTec, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtc#NASDAQ">MTC</a>) fell 22.4% to $1.82.</li>
<li>Evolve Transition Infrastructure LP (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snmp#NASDAQ">SNMP</a>) tumbled 20.8% to $1.33.</li>
<li>Revance Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvnc#NASDAQ">RVNC</a>) fell 20.1% to $6.68 after the company issued preliminary Q4 and FY23 financial results and guidance.</li>
<li>Banzai International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bnzi#NASDAQ">BNZI</a>) shares fell 19.3% to $2.07. Banzai shares jumped around 55% on Friday after the company signed an LOI to acquire IGLeads.</li>
<li>Northern Dynasty Minerals Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nak#NYSE">NAK</a>) dipped 18.8% to $0.3107.</li>
<li>The Arena Group Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aren#NYSE">AREN</a>) shares fell 18.2% to $1.7603 after dipping 17% on Friday.</li>
<li>The Arena Group Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aren#NASDAQ">AREN</a>) dipped 18% to $ 1.7650.</li>
<li>Inspire Veterinary Partners, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ivp#NASDAQ">IVP</a>) declined 16.8% to $0.1881. Inspire Veterinary Partners recently filed a prospectus related to up to a $5 million public offering</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pacb#NASDAQ">PACB</a>) fell 15.1% to $7.99. Pacific Biosciences of California said it sees preliminary FY23 revenue of $200.5 million.</li>
<li>REGENXBIO Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rgnx#NASDAQ">RGNX</a>) fell 14.8% to $14.01. US District Court issued decision on REGENXBIO and University of Pennsylvania NAV technology patent infringement lawsuit.</li>
<li>Revance Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvnc#NASDAQ">RVNC</a>) fell 13.6% to $7.21. Revance issued corporate update, preliminary Q4 and FY23 financial results, and financial outlook.</li>
<li>BioSig Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bsgm#NASDAQ">BSGM</a>) fell 13.6% to $0.35. On Jan. 5, BioSig Technologies received a letter from Nasdaq notifying company has regained compliance with Nasdaq Listing Rule 5550(b)(2).</li>
<li>Bright Health Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bhg#NYSE">BHG</a>) dipped 12.8% to $10.00.</li>
<li>Safe and Green Development Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgd#NASDAQ">SGD</a>) shares fell 11.3% to $1.80 after jumping 49% on Friday.</li>
<li>Argo Blockchain plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arbk#NASDAQ">ARBK</a>) fell 11.1% to $3.11 after announcing &pound;7.8 million ($9.9 million) placing.</li>
<li>Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/shph#NASDAQ">SHPH</a>) dipped 10.7% to $0.5146. Shuttle Pharmaceuticals received FDA approval to proceed with Phase II clinical trial of ropidoxuridine for the treatment of patients with glioblastoma.</li>
<li>Paragon 28, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fna#NYSE">FNA</a>) fell 9.6% to $11.83. Paragon 28 said it sees preliminary fourth-quarter revenue of $60.3 million to $60.6 million.</li>
<li>Sharps Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stss#NASDAQ">STSS</a>) fell 8.3% to $0.4032 after jumping 12% on Friday.</li>
<li>Dynavax Technologies Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dvax#NASDAQ">DVAX</a>) dipped 7.5% to $13.63. Dynavax sees preliminary 2023 HEPLISAV-B vaccine net product revenue of $213 million.</li>
<li>The Boeing Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ba#NYSE">BA</a>) fell 7% to $231.69 after an exit door blew out of a 737 aircraft during a commercial flight.</li>
<li>Spirit AeroSystems Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spr#NYSE">SPR</a>) fell 6.5% to $29.67 after an exit door blew out of a 737 aircraft during a commercial flight. Spirit Aerosystems was a vendor involved with the faulty door.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/01/36528274/cramer-says-this-major-healthcare-stock-is-ridiculously-cheap-and-doing-so-many-great-th"> Cramer Says This Major Healthcare Stock Is &#39;Ridiculously Cheap And Doing So Many Great Things&#39; </a>

Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Dynavax (DVAX) has provided an announcement. Effective August 1, 2024, Dynavax Technologies Corporation welcomes back Kelly MacDonald as Chief Fina...

Kelly MacDonald Returns as CFO to Dynavax Technologies

Dynavax GAAP EPS of $0.08 beats by $0.02, revenue of $73.8M misses by $2.24M

Dynavax Technologies Corporation (DVAX) Q2 2024 Earnings Call Transcript

In a report released yesterday, Phil Nadeau from TD Cowen maintained a Buy rating on Dynavax (DVAX – Research Report), with a price target of $25.0...

Dynavax's Strong Growth and Market Share Expansion Drive Buy Rating

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Dynavax Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/dvax-stock-quote/">DVAX</a>) just reported results for the second quarter of 2024.<ul><li>Dynavax Technologies reported earnings per share of 8 cents. This was above the analyst estimate for EPS of 6 cents.</li><li>The company reported revenue of $73.80 million.</li><li>This was 3.03% worse than the analyst estimate for revenue of $76.10 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/dvax-stock-earnings-dynavax-technologies-for-q2-of-2024/">DVAX Stock Earnings: Dynavax Technologies Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

DVAX Stock Earnings: Dynavax Technologies Beats EPS, Misses Revenue for Q2 2024

Analyst Roy Buchanan from JMP Securities reiterated a Buy rating on Dynavax (DVAX – Research Report) and keeping the price target at $29.00. Roy Bu...

Dynavax's Market Dominance and Buoyant Growth Prospects Affirm Buy Rating

3 Biotech Names To Target Now

Dynavax Technologies: A Two Trick Pony Operating With A Single Trick

Dynavax Technologies: Slow And Steady Wins The Race

50 stocks that may see selling pressure as investors begin looking to book tax losses

ACAD

APTV

ARCH

BIIB

CALX

ENOV

FOLD

GTLS

ICHR

MRTN

NEOG

NVEE

PLAB

PRGO

PTEN

RGEN

ROCK

SMPL

XNCR

XPEL

Press Releases

Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance

Dynavax to Present at TD Cowen's 44th Annual Health Care Conference

Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates

Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.

Dynavax to Present at Upcoming Investor Conferences

Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program

Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024

Dynavax Reports Second Quarter 2024 Financial Results and Provides Business Updates

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Dynavax Technologies

Dynavax Technologies (DVAX) Forecast

Dynavax Technologies (NASDAQ:DVAX) Stock, Quote.Headers.trade-ideas